BPC-157 / TB-500 Blend

This blend is used by researchers for tissue healing and recovery — it combines two peptides, BPC-157 (based on a stomach-protein fragment) and TB-500 (a fragment of thymosin beta-4), on the idea that pairing two different repair mechanisms produces a broader effect than either alone. Neither component is FDA-approved, and there's no brand-name product; most of the evidence behind each is in animals, and there are no published trials of the combination itself, so any added benefit over using either compound alone hasn't been confirmed in humans.

This blend combines BPC-157 and TB-500 for tissue healing and recovery. Most research on each component is in animals — those studies reported effects on healing, blood-vessel growth, and tissue remodeling. There are no published controlled trials of the combination, so any added benefit over either compound alone has not been confirmed in humans; the recovery uses people pursue rest on each component's preclinical data plus user reports.

Not FDA approved. Both components are non-approved and both were voted on at the FDA pcac 503A Bulks List meeting held July 23, 2026 (separate votes on the free base and the acetate of each; FDA's own briefing document proposed that none of those forms be included). FDA has published no summary minutes, vote results, or determination from that meeting as of 2026-09-03, and a PCAC recommendation is advisory and non-binding. Neither component is on the 503A Bulks List, so the most-restrictive-component rule is unchanged and the blend remains non-compoundable under 503A (as of 2026-09-03). Both components are also independently prohibited by WADA — BPC-157 under S0 (Non-Approved Substances, prohibited at all times) and TB-500 under S2.3 (Growth Factors) — so the blend is prohibited at all times in regulated sport on two independent grounds. See component entries for component-specific regulatory detail.

Both components are not FDA-approved, and their safety in humans has not been established in clinical trials. Both components are banned in regulated sport — BPC-157 under WADA S0 (non-approved substances, prohibited at all times) and TB-500 under WADA S2.3 (growth factors) — so the blend is prohibited on two independent grounds. VialWise is a research and educational reference, not medical advice — consult a licensed professional.

⚠️ For research and educational purposes only. Both components of this blend are not FDA approved, and both are independently prohibited by the World Anti-Doping Agency — BPC-157 under S0 (Non-Approved Substances, prohibited at all times) and TB-500 under S2.3 (Growth Factors). The blend is therefore prohibited at all times in regulated sport on two independent grounds, with S0 the most restrictive. Information in this entry is informational, not medical advice. Always confirm dose calculations with the in-app calculator and consult appropriate professional guidance before any protocol decisions.

⚠️ Precision matters at low doses. This blend's typical dosing produces draws in a wide range depending on reconstitution. Small dosing errors that look trivial in absolute terms can be significant in percentage terms when starting doses are small. Always verify draws against the in-app calculator and double-check the unit count on the syringe before injecting.

⚠️ There are no peer-reviewed RCTs of the BPC-157 + TB-500 combination. A PubMed search for the exact phrase combination of these two compounds returns four results as of May 2026 — all are review articles that discuss the two peptides in the broader context of musculoskeletal peptide therapy. None are RCTs of the combination itself. The blend's combined use is supported by (a) plausible complementary mechanisms extrapolated from each component's individual literature, (b) accumulated researcher experience, and (c) the related single-compound literatures, but not by direct evidence of additive or synergistic benefit over either compound alone.

⚠️ The blend dosing always involves a tradeoff. BPC-157's typical research-community dose is; TB-500's typical dose is — a roughly 10x difference. Pre-mixed blend products force a single combined dose decision: dosing at typical BPC-157 amounts means the TB-500 component is well below its single-compound research-community range; dosing at typical TB-500 amounts means the BPC-157 component is well above its range. There is no validated combined-dose protocol that satisfies both. Researchers using the blend should be explicit with themselves about which compound they are dose-anchoring on and why.

The BPC-157 / TB-500 blend is a pre-mixed lyophilized peptide product combining the pentadecapeptide BPC-157 and a synthetic fragment of thymosin beta-4 (sold as TB-500) in a single vial. It is one of the most commonly sold peptide blends in the research-peptide market and is the canonical "regenerative blend" referenced in researcher-community discussion of soft-tissue injury recovery.

The blend rationale. The two compounds have plausibly complementary mechanisms: BPC-157 is associated with angiogenesis (VEGF pathway), nitric oxide modulation, and tendon fibroblast activity;[¹: cross-reference to bpc-157.md sources] TB-500 (and by extrapolation from its parent molecule full thymosin beta-4) is associated with cell migration, actin-binding effects, and additional angiogenic and anti-inflammatory pathways.[²: cross-reference to tb-500.md sources] Researchers running the blend reason that combining a tendon/ligament-targeted compound (BPC-157) with a cell-migration / wound-healing compound (TB-500) covers more mechanism space during recovery than either alone.

What the published evidence does — and does not — show. As noted in the disclosure callout above, no peer-reviewed RCT has tested the BPC-157 + TB-500 combination against either compound alone or against placebo. Three recent (2026) review articles from major orthopedic and sports medicine journals discuss both peptides in the context of musculoskeletal peptide therapy, but each review treats them as separate compounds with separate evidence bases — none asserts that the combination has been shown to outperform either compound alone.[¹][²][³] A fourth recent review addresses the broader regenerative-peptide landscape in the context of healthy aging.[⁴]

Commercial product format vs simultaneous singles dosing. A "blend" product is a commercial convenience: it pre-combines the two compounds in a single lyophilized vial so the researcher reconstitutes once and draws once. Pharmacologically, this is equivalent to reconstituting each single separately and dosing them at the same time — except for the dosing tradeoff noted in the callout above. Researchers who want full control over the BPC and TB doses independently should use the singles (see the standalone entries [bpc-157.md](./bpc-157.md) and [tb-500.md](./tb-500.md)) rather than a pre-mixed blend.

Dosing tradeoff in detail. This is the single most important practical consideration unique to the blend format. The single-compound research-community typical dose ranges differ by approximately 10x:

A 1:1 pre-mixed blend cannot satisfy both ranges simultaneously. Common blend dosing patterns therefore fall into three groups:

1. BPC-anchored dosing ( of each per dose): the TB-500 component is well below its single-compound range. This is the most common research-community pattern for regular use. 2. TB-anchored dosing ( of each per dose): the BPC-157 component is significantly above its single-compound range. Less commonly reported and increases per-dose cost substantially. 3. Compromise dosing (~ of each per dose): a midpoint that exceeds typical BPC-157 and falls short of typical TB-500. Sometimes reported during loading phases.

No protocol from any of these three patterns is validated in published research. The choice between them is a researcher judgment about which compound's effects are being prioritized.

Commonly reported

• Combined angiogenic activity. Both components have been described as promoting angiogenesis. The combined effect is not characterized in published literature — there is no peer-reviewed evidence that the combined angiogenic effect is greater (or lesser) than either compound alone. The theoretical contraindication for active or undiagnosed malignancy applies with both components present.
• Injection site reactions. Combined use does not appear to elevate injection-site reaction rates beyond what either single produces, based on research-community reports.
• No combined-dose toxicology data exists. The component compounds have limited published human safety data individually; the combination has none.

Active malignancy or undiagnosed cancer concern — theoretical contraindication based on both components' angiogenic mechanisms (BPC-157 vegf promotion + TB-500-derived Tβ4 angiogenesis). The combined-use evidence base is silent on whether this concern compounds.

Pregnancy and lactation: no data; default to contraindicated — applies to both components individually and to the blend.

Pediatric use: no data — should not be used in researchers under 18.

WADA-prohibited in regulated sport — both components independently trigger this. BPC-157 is listed under S0 (Non-Approved Substances), prohibited at all times, explicitly named on the 2026 Prohibited List; TB-500 (thymosin β4 derivatives) is listed under S2.3 (Growth Factors). Under the most-restrictive-component rule, S0 governs: the blend is prohibited at all times. Researchers competing in any WADA-tested sport, or in regulated equine racing, will test positive.

US compounding status — under review, determination pending. Neither component is FDA-approved and neither is Category 1 / compoundable. BPC-157 was removed from FDA 503A bulks list Category 2 in ~April 2026 — removal is not approval and does not make it compoundable; it moves the compound into a transitional gray area pending formal evaluation. Both BPC-157 and TB-500 (free base and acetate) are named subjects of the FDA pcac 503A Bulks List review at the July 23–24, 2026 meeting, and FDA briefing materials propose against adding either. The review has since taken place (July 23, 2026) and the committee voted, but FDA has published no minutes, vote results, or determination as of 2026-09-03 — nothing has been decided by FDA. `[confirm the final PCAC outcome — FDA had published no minutes, vote results, or determination as of 2026-09-03; re-check before App Store submission]` See component entries for component-specific detail.

Peptide

A short chain of amino acids, the building blocks of proteins. Many compounds in this library are peptides.

Blend

a single product combining two or more compounds.

Preclinical

Research done in cells or animals, before human clinical trials. Promising preclinical results don't always hold up in people.

Subcutaneous

An injection into the fatty layer just under the skin, rather than into a muscle or vein.

WADA Prohibited List

The list of substances banned in regulated sport by the World Anti-Doping Agency.

1. Mendias CL, Awan TM. (2026). Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Medicine (online ahead of print; accepted 24 March 2026, published 12 April 2026, version of record 12 April 2026).(PMID 41966639)
2. Rahman OF, Lee SJ, Seeds WA. (2026). Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. JAAOS Global Research & Reviews, 10(1):e25.00236 (eCollection January 2, 2026).(PMID 41490200)
3. Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. (2026). Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. American Journal of Sports Medicine, 54(1):223–229 (January 2026 print issue).(PMID 41476424)
4. World Anti-Doping Agency. The 2026 Prohibited List, International Standard (effective 1 January 2026). Canonical PDF: wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf (linked from the WADA landing page at wada-ama.org/en/prohibited-list; local archival copy in `docs/legal/wada-2026-prohibited-list.pdf`). TB-500 is named explicitly under Section S2.3 (Growth Factors and Growth Factor Modulators) — not under S2.2. Verbatim wording from the canonical PDF, page 8: "Thymosin-ß4 and its derivatives e.g. TB-500" — listed alongside Fibroblast growth factors (FGFs), Hepatocyte growth factor (HGF), Insulin-like growth factor 1 (IGF-1, mecasermin) and its analogues, Mechano growth factors (MGFs), Platelet-derived growth factor (PDGF), and Vascular endothelial growth factor (VEGF). The S2.3 catch-all clause reads verbatim: "and other growth factors or growth factor modulators affecting muscle, tendon or ligament protein synthesis/degradation, vascularisation, energy utilization, regenerative capacity or fibre type switching." Prohibited at all times.

• ARA-290 — same mechanism class
• BPC-157 — same mechanism class
• GHK-Cu — same mechanism class
• GLOW — same mechanism class
• KLOW — same mechanism class
• TB-500 — same mechanism class